Erasca, Inc.
Erasca (Nasdaq: ERAS) is a clinical-stage precision oncology company developing therapies for cancers driven by alterations in the RAS/MAPK pathway. Its drug-development pipeline uses small- and large-molecule approaches to target pathway signaling nodes, RAS directly, and mechanisms that enable tumors to escape… From the company’s description.
In fiscal 2025, Erasca, Inc. reported a net loss of $124.55M. Operations used $95.45M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Erasca, Inc. does
In the company’s own words
Erasca (Nasdaq: ERAS) is a clinical-stage precision oncology company developing therapies for cancers driven by alterations in the RAS/MAPK pathway. Its drug-development pipeline uses small- and large-molecule approaches to target pathway signaling nodes, RAS directly, and mechanisms that enable tumors to escape treatment; programs are intended for development as single agents and in combinations. Clinical-stage candidates include ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, while discovery-stage ERAS-12 is an EGFR biparatopic antibody. The company’s programs address potential treatment approaches across solid tumors, including colorectal, pancreatic and non-small-cell lung cancers. Erasca has worldwide development and commercial rights to its pipeline, which includes programs acquired or licensed from external companies; it in-licensed its RAS-targeting franchise in 2024 and discontinued development of naporafenib in 2025 to prioritize that franchise. The company was founded to focus on precision oncology and RAS targeting. Its website is www.erasca.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1761918
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Erasca, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Erasca, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Erasca, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Erasca, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Erasca, Inc.'s last four quarterly filings that the numbers alone won't show?”